Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | LIPC | P11150 | 9/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | RRM1 | P23921 | 1/20 | 0.32 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2798695 | 0.94 | LIPC (0.37) | METAP2LIPCLIPGMMP13BRAF | |
| SCHEMBL2798119 | 0.87 | MMP13 (0.34) | METAP2LIPCLIPGMMP13 | |
| SCHEMBL2797455 | 0.87 | LIPC (0.33) | LIPCLIPGMMP13BRAF | |
| SCHEMBL2794552 | 0.87 | LIPC (0.34) | LIPCLIPGBRAF | |
| SCHEMBL2798256 | 0.86 | MMP13 (0.33) | METAP2LIPCMMP13SCN9A | |
| SCHEMBL2799420 | 0.86 | MMP13 (0.33) | METAP2LIPCMMP13 | |
| SCHEMBL2795101 | 0.86 | LIPC (0.35) | LIPCLIPGBRAF | |
| SCHEMBL2797696 | 0.84 | LIPC (0.35) | LIPCLIPGBRAF | |
| SCHEMBL13262581 | 0.84 | MAOB (0.37) | LIPCLIPGBRAFSCN5ASCN9A | |
| SCHEMBL2796376 | 0.82 | LIPC (0.34) | LIPCLIPGBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2204365-A1 | ALKYLSULFONE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-20100168136-A1 | ALKYLSULFONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168136-A1 | ALKYLSULFONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168136-A1 | ALKYLSULFONE DERIVATIVES | BACE1, APP, AMY1A | METAP2 854/4885LIPC 1380/4885LIPG 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.